Trombosis asociada a asparaginasa en niños con leucemia linfoblástica aguda.

Asparaginase-related thrombosis in children with acute lymphoblastic leukemia.

Publicado 2018-07-01

Abrir | Descargar
PDF FLIP
Número
Vol. 5 Núm. 1 (2018): Julio
Sección
Revisiones
Cómo citar
Trombosis asociada a asparaginasa en niños con leucemia linfoblástica aguda.
Rev. colomb. hematol. oncol. [Internet]. 2018 Jul. 1 [cited 2024 Dec. 22];5(1):72-8. Disponible en: https://doi.org/10.51643/22562915.365
DOI

https://doi.org/10.51643/22562915.365
Dimensions
PlumX
Licencia
Creative Commons License

Esta obra está bajo una licencia internacional Creative Commons Atribución-NoComercial-CompartirIgual 4.0.

Carolina Casas
Hospital Infantil Napoleón Franco Pareja
    Gloria Ramos
    Hospital Militar Central
      Óscar Eduardo González
      Fundación Santa Fe de Bogotá
        Federico Arroyave
        Universidad Militar Nueva Granada
          Mostrar biografía de los autores

          Carolina Casas,

          Médica especialista en hematooncología pediátrica. Hospital Infantil Napoleón Franco Pareja (Cartagena).

          Gloria Ramos,

          Bacterióloga especialista en hemostasia. Hospital Militar Central. Laboratorio de Referencia en Hemostasia y Hematología H&H Lab (Bogotá).

          Óscar Eduardo González,

          Médico especialista en hematooncología pediátrica. Fundación Santa Fe. Hospital Central de la Policía Nacional (Bogotá).

          Federico Arroyave,

          Médico especialista en hematooncología pediátrica. Universidad Militar Nueva Granada (Bogotá).

          La asparaginasa es un medicamento fundamental en el tratamiento contra la leucemia linfoblástica aguda. Su uso se asocia a disminución en la síntesis de proteínas que intervienen en el proceso de coagulación y fibrinolisis, lo que conlleva complicaciones trombóticas. La ocurrencia de estos eventos se ha informado después del inicio del tratamiento, reflejando así una posible interacción entre la enfermedad y la terapia.

          Visitas del artículo 416 | Visitas PDF 1464

          1. Silverman LB, Declerck L, Gelber RD, Dalton VK, Asselin BL, Barr RD, et al. Results of Dana-Farber Cancer Institute Consortium protocols for children with newly diagnosed acute lymphoblastic leukemia (1981-1995). Leukemia. 2000;14(12):2247-56.
          2. Silverman LB, Gelber RD, Dalton VK, Asselin BL, Barr RD, Clavell LA, et al. Improved outcome for children with acute lymphoblastic leukemia: results of Dana-Farber Consortium Protocol 91-01. Blood. 2001;97(5):1211-8.
          3. Pui CH, Sandlund JT, Pei D, Campana D, Rivera GK, Ribeiro RC, et al. Improved outcome for children with acute lymphoblastic leukemia: results of Total Therapy Study XIIIB at St Jude Children’s Research Hospital. Blood. 2004;104(9):2690-6.
          4. Pui CH, Campana D, Pei D, Bowman WP, Sandlund JT, Kaste SC, et al. Treating childhood acute lymphoblastic leukemia without cranial irradiation. N Engl J Med. 2009;360(26):2730-41.
          5. Möricke A, Reiter A, Zimmermann M, Gadner H, Stanulla M, Dördelmann M, et al. Risk-adjusted therapy of acute lymphoblastic leukemia can decrease treatment burden and improve survival: treatment results of 2169 unselected pediatric and adolescent patients enrolled in the trial ALL-BFM 95. Blood. 2008;111(9):4477-89.
          6. Raetz EA, Salzer WL. Tolerability and efficacy of L-asparaginase therapy in pediatric patients with acute lymphoblastic leukemia. J Pediatr Hematol Oncol. 2010;32(7):554-63.
          7. Athale UH, Chan AK. Thrombosis in children with acute lymphoblastic leukemia: Part II. Pathogenesis of thrombosis in children with acute lymphoblastic leukemia: effects of the disease and therapy. Thromb Res. 2003;111(4-5):199-212.
          8. Pieters R, Hunger SP, Boos J, Rizzari C, Silverman L, Baruchel A, et al. L-asparaginase treatment in acute lymphoblastic leukemia: a focus on Erwinia asparaginase. Cancer. 2011;117(2):238-49.
          9. Rizzari C, Conter V, Starý J, Colombini A, Moericke A, Schrappe M. Optimizing asparaginase therapy for acute lymphoblastic leukemia. Curr Opin Oncol. 2013;25 Suppl 1:S1-9.
          10. Andrade AF, Borges KS, Silveira VS. Update on the use of Lasparaginase in infants and adolescent patients with acute lymphoblastic leukemia. Clin Med Insights Oncol. 2014;8:95-100.
          11. Athale UH, Chan AK. Thrombosis in children with acute lymphoblastic leukemia: part I. Epidemiology of thrombosis in children with acute lymphoblastic leukemia. Thromb Res. 2003;111(3):125-31.
          12. Giordano P, Molinari AC, Del Vecchio GC, Saracco P, Russo G, Altomare M, et al. Prospective study of hemostatic alterations in children with acute lymphoblastic leukemia. Am J Hematol. 2010;85(5):325-30.
          13. Grace RF, Dahlberg SE, Neuberg D, Sallan SE, Connors JM, Neufeld EJ, et al. The frequency and management of asparaginaserelated thrombosis in paediatric and adult patients with acute lymphoblastic leukaemia treated on Dana-Farber Cancer Institute consortium protocols. Br J Haematol. 2011;152(4):452-9.
          14. Lejhancova-Tousovska K, Zapletal O, Vytiskova S, Strbackova P, Sterba J. Profile of thrombin generation in children with acute lymphoblastic leukemia treated by Berlin-Frankfurt-Münster (BFM) protocols. Blood Coagul Fibrinolysis. 2012;23(2):144-54.
          15. Rickles FR, Falanga A, Montesinos P, Sanz MA, Brenner B, Barbui T. Bleeding and thrombosis in acute leukemia: what does the future of therapy look like? Thromb Res. 2007;120 Suppl 2:S99-106.
          16. Athale UH, Chan AK. Thrombosis in children with acute lymphoblastic leukemia. Part II. Pathogenesis of thrombosis in children with acute lymphoblastic leukemia: effects of the disease and therapy. Thromb Res. 2003;111(4-5):199-212.
          17. Priest JR, Ramsay NK, Steinherz PG, Tubergen DG, Cairo MS, Sitarz AL, et al. A syndrome of thrombosis and hemorrhage complicating L-asparaginase therapy for childhood acute lymphoblastic leukemia. J Pediatr. 1982;100(6):984-9.
          18. Shapiro AD, Clarke SL, Christian JM, Odom LF, Hathaway WE. Thrombosis in children receiving L-asparaginase. Determining patients at risk. Am J Pediatr Hematol Oncol. 1993;15(4):400-5.
          19. Nowak-Göttl U, Heinecke A, von Kries R, Nürnberger W, Münchow N, Junker R. Thrombotic events revisited in children with acute lymphoblastic leukemia: impact of concomitant Escherichia coli asparaginase/prednisone administration. Thromb Res. 2001;103(3):165-72.
          20. Stief TW, Chalkitis D. Asparaginase modulates thrombin generation. Hemostasis Lab. 2008;1:303-66.
          21. Ranta S, Heyman MM, Jahnukainen K, Taskinen M, SaarinenPihkala UM, Frisk T, et al. Antithrombin deficiency after prolonged asparaginase treatment in children with acute lymphoblastic leukemia. Blood Coagul Fibrinolysis. 2013;24(7):749-56.
          22. Bushman JE, Palmieri D, Whinna HC, Church FC. Insight into the mechanism of asparaginase-induced depletion of antithrombin III in treatment of childhood acute lymphoblastic leukemia. Leuk Res. 2000;24(7):559-65.
          23. Beinart G, Damon L. Thrombosis associated with L-asparaginase therapy and low fibrinogen levels in adult acute lymphoblastic leukemia. Am J Hematol. 2004;77(4):331-5.
          24. Girolami A, Ruzzon E, Tezza F, Scandellari R, Vettore S, Girolami B. Arterial and venous thrombosis in rare congenital bleeding disorders: a critical review. Haemophilia. 2006;12(4):345-51.
          25. Albayrak M, Gürsel T, Kaya Z, Koçak U. Alterations in procoagulant, anticoagulant, and fibrinolytic systems before and after start of induction chemotherapy in children with acute lymphoblastic leukemia. Clin Appl Thromb Hemost. 2013;19(6):644-51.
          26. Pui CH, Chesney CM, Bergum PW, Jackson CW, Rapaport SI. Lack of pathogenetic role of proteins C and S in thrombosis associated with asparaginase-prednisone-vincristine therapy for leukaemia. Br J Haematol. 1986;64(2):283-90.
          27. Schneider P, Van Dreden P, Rousseau A, Kassim Y, Legrand E, Vannier JP, et al. Increased levels of tissue factor activity and procoagulant phospholipids during treatment of children with acute lymphoblastic leukaemia. Br J Haematol. 2010;148(4):582-92.
          28. Mitchell L, Lambers M, Flege S, Kenet G, Li-Thiao-Te V, Holzhauer S, et al. Validation of a predictive model for identifying an increased risk for thromboembolism in children with acute lymphoblastic leukemia: results of a multicenter cohort study. Blood. 2010;115(24):4999-5004.
          29. Qureshi A, Mitchell C, Richards S, Vora A, Goulden N. Asparaginase-related venous thrombosis in UKALL 2003- reexposure to asparaginase is feasible and safe. Br J Haematol. 2010;149(3):410-3.
          30. Grace RF, Dahlberg SE, Neuberg D, Sallan SE, Connors JM, Neufeld EJ, et al. The frequency and management of asparaginaserelated thrombosis in paediatric and adult patients with acute lymphoblastic leukaemia treated on Dana-Farber Cancer Institute consortium protocols. Br J Haematol. 2011;152(4):452-9.
          31. Hijiya N, Van der Sluis IM. Asparaginase-associated toxicity in children with acute lymphoblastic leukemia. Leuk Lymphoma. 2016;57(4):748-57.
          32. Franchini M, Lippi G. Fibrinogen replacement therapy: a critical review of the literature. Blood Transfus. 2012;10(1):23-7.
          33. Astwood E, Vora A. Personal practice: how we manage the risk of bleeding and thrombosis in children and young adults with acute lymphoblastic leukemia. Br J Haematol 2011;152(5):505-11.

          Información

          Directorios e indexadores
          Perfil de Google Scholar

          Código QR

          Palabras clave

          Más leídos en los últimos 30 días

          Número actual

          Sistema OJS 3.4.0.7 - Metabiblioteca |